Trial Profile
A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 30 Apr 2022 Combined results of phase II studies (NCT03278405 and NCT03278379) assessing the efficacy and safety of avelumab, a PD-L1-directed antibody, in patients with advanced unresectable/metastatic higher grade NENs, published in the European Journal of Cancer.
- 17 Mar 2020 Status changed from recruiting to completed.
- 06 Feb 2018 Status changed from not yet recruiting to recruiting.